An Open-Label Safety, Tolerability, and Efficacy Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 16 Oct 2018
At a glance
- Drugs ATI 502 (Primary)
- Indications Alopecia
- Focus Therapeutic Use
- Sponsors Aclaris Therapeutics
- 09 Oct 2018 Status changed from recruiting to active, no longer recruiting.
- 23 Apr 2018 According to Aclaris Therapeutics media release, first patient has been dosed.
- 15 Mar 2018 New trial record